June 5th 2025
Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.
Watch
Infectious Disease Professionals: Mosquito-Borne Pathogens are Priority Concerns for Outbreaks
September 22nd 2024A new survey reveals that infectious disease virologists, epidemiologists and clinicians see the need to address gaps in surveillance programs to identify emerging pathogens, public health funding and testing infrastructure capabilities.
Read More
A Novel Approach to Infectious Disease Surveillance
September 16th 2024The International Society for Infectious Diseases (ISID) ProMED surveillance system is a way for clinicians and interested ID stakeholders to be aware of local outbreaks and follow-up in response to get more information on them.
Watch
Mpox Vaccine Manufacturer is Prepared to Increase Production
August 19th 2024Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.
Read More
Mpox and Concerns Around the Disease in the United States
August 15th 2024Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.
Watch
First Doses of R21/Matrix-M Malaria Vaccine Administered in Ivory Coast
July 19th 2024With an efficacy rate of 78% and WHO prequalification, the vaccine rollout aims to vaccinate 6.6 million children across 15 African countries by the end of 2024, marking an advancement in public health efforts to combat malaria's impact
Read More